These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1078 related items for PubMed ID: 21939718

  • 1. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 2. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 3. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS, Vyas SP.
    Vaccine; 2006 May 08; 24(19):4201-11. PubMed ID: 16446012
    [Abstract] [Full Text] [Related]

  • 4. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.
    Vaccine; 2012 Jul 06; 30(32):4884-91. PubMed ID: 22537989
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 8. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A.
    Int Immunopharmacol; 2008 Dec 20; 8(13-14):1773-80. PubMed ID: 18801462
    [Abstract] [Full Text] [Related]

  • 9. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, Takahashi M, Yamanishi K, Mori Y.
    Vaccine; 2009 Sep 25; 27(42):5896-905. PubMed ID: 19647814
    [Abstract] [Full Text] [Related]

  • 10. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2010 Jan 25; 82(1):128-37. PubMed ID: 19950232
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.
    Vaccine; 2012 Jan 05; 30(2):466-74. PubMed ID: 22051136
    [Abstract] [Full Text] [Related]

  • 13. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S, Yoshii H, Akagi T, Akashi M, Ishikawa T, Okuno Y, Takahashi M, Yamanishi K, Mori Y.
    Vaccine; 2007 Nov 28; 25(49):8270-8. PubMed ID: 17977633
    [Abstract] [Full Text] [Related]

  • 14. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel J.
    J Clin Virol; 2004 Dec 28; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, Spira J, Goldwaser I, Ellis R, Barenholz Y.
    Vaccine; 2010 Sep 07; 28(39):6527-41. PubMed ID: 20412874
    [Abstract] [Full Text] [Related]

  • 16. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
    Moon HJ, Lee JS, Talactac MR, Chowdhury MY, Kim JH, Park ME, Choi YK, Sung MH, Kim CJ.
    Vet Microbiol; 2012 Dec 07; 160(3-4):277-89. PubMed ID: 22763171
    [Abstract] [Full Text] [Related]

  • 17. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Fang F, Zheng M, Chen Z.
    Vaccine; 2010 Nov 10; 28(48):7690-8. PubMed ID: 20870054
    [Abstract] [Full Text] [Related]

  • 18. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.
    Vajdy M, Baudner B, Del Giudice G, O'Hagan D.
    Clin Immunol; 2007 May 10; 123(2):166-75. PubMed ID: 17349825
    [Abstract] [Full Text] [Related]

  • 19. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.
    Vaccine; 2010 Nov 23; 28(50):7963-9. PubMed ID: 20946860
    [Abstract] [Full Text] [Related]

  • 20. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS, Lee KA, Lee JY, Kang MH, Song YC, Baek DJ, Kim S, Kang CY.
    Vaccine; 2011 Jan 10; 29(3):417-25. PubMed ID: 21087689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.